

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3696472/publications.pdf>

Version: 2024-02-01

69
papers

5,661
citations

117625

34
h-index

95266

68
g-index

69
all docs

69
docs citations

69
times ranked

7596
citing authors

#	ARTICLE	IF	CITATIONS
1	High serum soluble CD155 level predicts poor prognosis and correlates with an immunosuppressive tumor microenvironment in hepatocellular carcinoma. <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24259.	2.1	10
2	Whole-genome sequencing reveals the evolutionary trajectory of HBV-related hepatocellular carcinoma early recurrence. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 24.	17.1	7
3	Hsa_circ_0003945 promotes progression of hepatocellular carcinoma by mediating miR-34c-5p/LGR4/ β -catenin axis activity. <i>Journal of Cellular and Molecular Medicine</i> , 2022, , .	3.6	4
4	An SCD1-dependent mechanoresponsive pathway promotes HCC invasion and metastasis through lipid metabolic reprogramming. <i>Molecular Therapy</i> , 2022, 30, 2554-2567.	8.2	24
5	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis. <i>Clinical and Translational Medicine</i> , 2022, 12, e794.	4.0	13
6	Circulating tumor cell detection and single-cell analysis using an integrated workflow based on ChimeraX [®] 120 Platform: A prospective study. <i>Molecular Oncology</i> , 2021, 15, 2345-2362.	4.6	9
7	Detection of circulating tumour cells enables early recurrence prediction in hepatocellular carcinoma patients undergoing liver transplantation. <i>Liver International</i> , 2021, 41, 562-573.	3.9	32
8	Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF- κ B signaling pathways synergistically. <i>Clinical and Translational Medicine</i> , 2021, 11, e335.	4.0	27
9	Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. <i>Frontiers in Oncology</i> , 2021, 11, 704042.	2.8	5
10	Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 4091.	12.8	90
11	Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation. <i>Journal of Cancer</i> , 2021, 12, 7190-7200.	2.5	5
12	Mucin 1 promotes tumor progression through activating WNT/ β -catenin signaling pathway in intrahepatic cholangiocarcinoma. <i>Journal of Cancer</i> , 2021, 12, 6937-6947.	2.5	8
13	Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification. <i>International Journal of Cancer</i> , 2020, 146, 1606-1617.	5.1	32
14	Elevated soluble programmed death-ligand 1 levels indicate immunosuppression and poor prognosis in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization. <i>Clinica Chimica Acta</i> , 2020, 511, 67-74.	1.1	8
15	Effect of surgical margin on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma. <i>EBioMedicine</i> , 2020, 62, 103107.	6.1	23
16	Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolization in hepatocellular carcinoma: A single-center, retrospective, propensity-matched study. <i>Clinical and Translational Medicine</i> , 2020, 10, e137.	4.0	25
17	Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. <i>Cell Death and Disease</i> , 2020, 11, 573.	6.3	65
18	Targeted therapy for hepatocellular carcinoma. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 146.	17.1	320

#	ARTICLE	IF	CITATIONS
19	BCL11B suppresses tumor progression and stem cell traits in hepatocellular carcinoma by restoring p53 signaling activity. <i>Cell Death and Disease</i> , 2020, 11, 895.	6.3	11
20	CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5- β -catenin oncogenic signaling. <i>Clinical and Translational Medicine</i> , 2020, 10, e233.	4.0	51
21	Postoperative circulating tumor cells: An early predictor of extrahepatic metastases in patients with hepatocellular carcinoma undergoing curative surgical resection. <i>Cancer Cytopathology</i> , 2020, 128, 733-745.	2.4	19
22	Limited bias effect of intratumoral heterogeneity on genetic profiling of hepatocellular carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 112-120.	1.4	2
23	KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition. <i>Journal of Cancer</i> , 2019, 10, 3914-3925.	2.5	27
24	Sphere-forming culture enriches liver cancer stem cells and reveals Stearoyl-CoA desaturase 1 as a potential therapeutic target. <i>BMC Cancer</i> , 2019, 19, 760.	2.6	78
25	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. <i>Journal of Hepatology</i> , 2019, 71, 1152-1163.	3.7	49
26	Chemotherapeutic perfusion of portal vein after tumor thrombectomy and hepatectomy benefits patients with advanced hepatocellular carcinoma: A propensity score-matched survival analysis. <i>Cancer Medicine</i> , 2019, 8, 6933-6944.	2.8	14
27	CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K/AKT signaling by inducing Rap1-mediated membrane localization of P110 β and predicts poor prognosis. <i>Journal of Hematology and Oncology</i> , 2019, 12, 37.	17.0	150
28	A Positive Feedback Loop Between Cancer Stem-Like Cells and Tumor-Associated Neutrophils Controls Hepatocellular Carcinoma Progression. <i>Hepatology</i> , 2019, 70, 1214-1230.	7.3	140
29	A novel, liver-specific long noncoding RNA LINC01093 suppresses HCC progression by interaction with IGF2BP1 to facilitate decay of GLI1 mRNA. <i>Cancer Letters</i> , 2019, 450, 98-109.	7.2	94
30	Clinical Characteristics and Prognostic Factors of Patients with Intrahepatic Cholangiocarcinoma with Fever: A Propensity Score Matching Analysis. <i>Oncologist</i> , 2019, 24, 997-1007.	3.7	9
31	ASO Author Reflections: Annexin A3 as a Potential Biomarker for Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 529-530.	1.5	1
32	Application of Serum Annexin A3 in Diagnosis, Outcome Prediction and Therapeutic Response Evaluation for Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2018, 25, 1686-1694.	1.5	25
33	Circulating Tumor Cells with Stem-Like Phenotypes for Diagnosis, Prognosis, and Therapeutic Response Evaluation in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 2203-2213.	7.0	102
34	Circulating Tumor Cells from Different Vascular Sites Exhibit Spatial Heterogeneity in Epithelial and Mesenchymal Composition and Distinct Clinical Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 547-559.	7.0	112
35	BAP1 acts as a tumor suppressor in intrahepatic cholangiocarcinoma by modulating the ERK1/2 and JNK/c-Jun pathways. <i>Cell Death and Disease</i> , 2018, 9, 1036.	6.3	31
36	Significance of PIVKA-II levels for predicting microvascular invasion and tumor cell proliferation in Chinese patients with hepatitis B virus-associated hepatocellular carcinoma. <i>Oncology Letters</i> , 2018, 15, 8396-8404.	1.8	13

#	ARTICLE	IF	CITATIONS
37	PDXliver: a database of liver cancer patient derived xenograft mouse models. BMC Cancer, 2018, 18, 550.	2.6	20
38	Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 293-301.	3.7	79
39	A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections. Lipids in Health and Disease, 2017, 16, 123.	3.0	11
40	Circulating CD14 ⁺ HLA-DR ^{low} myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatology Research, 2017, 47, 1061-1071.	3.4	56
41	STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4. Molecular Cancer, 2017, 16, 136.	19.2	434
42	Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. Journal of Cancer, 2017, 8, 1338-1346.	2.5	11
43	HOXB7 promotes tumor progression via bFGF-induced activation of MAPK/ERK pathway and indicated poor prognosis in hepatocellular carcinoma. Oncotarget, 2017, 8, 47121-47135.	1.8	29
44	Low expression is associated with poor prognosis in patients with hepatocellular carcinoma. American Journal of Cancer Research, 2017, 7, 2465-2477.	1.4	5
45	Prognostic value of fever grade combined with neutrophil percentage in hepatocellular carcinoma patients presenting fever as the initial manifestation. OncoTargets and Therapy, 2016, Volume 9, 6281-6290.	2.0	5
46	Apolipoprotein A1: a novel serum biomarker for predicting the prognosis of hepatocellular carcinoma after curative resection. Oncotarget, 2016, 7, 70654-70668.	1.8	44
47	Application of the albumin-bilirubin grade for predicting prognosis after curative resection of patients with early-stage hepatocellular carcinoma. Clinica Chimica Acta, 2016, 462, 15-22.	1.1	47
48	Dynamic change of the systemic immune inflammation index predicts the prognosis of patients with hepatocellular carcinoma after curative resection. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1963-1969.	2.3	61
49	Liquid Biopsy and its Potential for Management of Hepatocellular Carcinoma. Journal of Gastrointestinal Cancer, 2016, 47, 157-167.	1.3	27
50	High level of serum protein DKK1 predicts poor prognosis for patients with hepatocellular carcinoma after hepatectomy. Hepatic Oncology, 2015, 2, 231-244.	4.2	13
51	Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma. Cancer Letters, 2015, 366, 112-122.	7.2	21
52	A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma. Biochemical and Biophysical Research Communications, 2015, 468, 525-532.	2.1	59
53	Systemic Immune-Inflammation Index Predicts Prognosis of Patients after Curative Resection for Hepatocellular Carcinoma. Clinical Cancer Research, 2014, 20, 6212-6222.	7.0	1,012
54	Clinical Significance of <i>EpCAM</i> mRNA-Positive Circulating Tumor Cells in Hepatocellular Carcinoma by an Optimized Negative Enrichment and qRT-PCR-Based Platform. Clinical Cancer Research, 2014, 20, 4794-4805.	7.0	99

#	ARTICLE	IF	CITATIONS
55	MiR-146a enhances angiogenic activity of endothelial cells in hepatocellular carcinoma by promoting PDGFRA expression. <i>Carcinogenesis</i> , 2013, 34, 2071-2079.	2.8	109
56	Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection. <i>Hepatology</i> , 2013, 57, 1458-1468.	7.3	331
57	High expression of Dickkopf-related protein 1 is related to lymphatic metastasis and indicates poor prognosis in intrahepatic cholangiocarcinoma patients after surgery. <i>Cancer</i> , 2013, 119, 993-1003.	4.1	73
58	Hypoxia inducible factor 2 alpha inhibits hepatocellular carcinoma growth through the transcription factor dimerization partner 3/ E2F transcription factor 1-dependent apoptotic pathway. <i>Hepatology</i> , 2013, 57, 1088-1097.	7.3	74
59	Prognostic Significance of Capn4 Overexpression in Intrahepatic Cholangiocarcinoma. <i>PLoS ONE</i> , 2013, 8, e54619.	2.5	43
60	Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. <i>Lancet Oncology</i> , The, 2012, 13, 817-826.	10.7	337
61	Dickkopf-1 and hepatocellular carcinoma – Authors' reply. <i>Lancet Oncology</i> , The, 2012, 13, e410-e411.	10.7	0
62	Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 1312-1319.	2.8	52
63	Circulating tumor cells: advances in detection methods, biological issues, and clinical relevance. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 1151-1173.	2.5	160
64	High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. <i>Gut</i> , 2010, 59, 953-962.	12.1	238
65	Up-regulation of KrÄppel-Like Factor 8 Promotes Tumor Invasion and Indicates Poor Prognosis for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2010, 139, 2146-2157.e12.	1.3	88
66	CD24 Is a Novel Predictor for Poor Prognosis of Hepatocellular Carcinoma after Surgery. <i>Clinical Cancer Research</i> , 2009, 15, 5518-5527.	7.0	122
67	Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1155-1163.	2.5	154
68	Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection. <i>Clinical Cancer Research</i> , 2008, 14, 3850-3859.	7.0	143
69	Osteopontin Combined with CD44, a Novel Prognostic Biomarker for Patients with Hepatocellular Carcinoma Undergoing Curative Resection. <i>Oncologist</i> , 2008, 13, 1155-1165.	3.7	69